A new study and the findings give hope. Innovative therapies have been proven to work in the long term and show a dramatic increase in patient survival. One of the tumors more complex, which at lung achieved a good result thanks to the combination of pembrolizumab, an immunotherapy molecule, with chemotherapy.
A first step forward confirms that one in five patients is actually alive by the age of 5. That combination of molecule and chemotherapy reduced the risk by 40% and doubled to five years over there survival global. We assume that with chemotherapy alone, survival was 10.6 months.
Another study involving patients with squamous histology the survival rate doubled compared to using chemotherapy alone. There are other good results for forms of cancer of gene mutations. For example, in early stage non-small cell lung cancer with mutations in the epidermal growth factor receptor (EGFR). After surgery, the use of the osimertinib molecule achieved an average survival of 5 and a half years.
The benefits obtained, namely a 73% reduction in the risk of relapse or death in the global population and a median disease-free survival of approximately five and a half years, are truly significant and define a new standard of care, in light of an excellent tolerability.
Filippo de Marinis, Director of the Thoracic Oncology Department of the European Institute of Oncology (IEO) in Milan
Source: Lega Nerd
I am Bret Jackson, a professional journalist and author for Gadget Onus, where I specialize in writing about the gaming industry. With over 6 years of experience in my field, I have built up an extensive portfolio that ranges from reviews to interviews with top figures within the industry. My work has been featured on various news sites, providing readers with insightful analysis regarding the current state of gaming culture.
